A worldwide comparison of the management of surgical treatment of advanced oral cancer

Publication date: Available online 8 January 2018
Source:Journal of Cranio-Maxillofacial Surgery
Author(s): Katinka Kansy, Andreas Albert Mueller, Thomas Mücke, Friederike Koersgen, Klaus Dietrich Wolff, Hans-Florian Zeilhofer, Frank Hölzle, Winnie Pradel, Matthias Schneider, Andreas Kolk, Ralf Smeets, Julio Acero, Piet Haers, G.E. Ghali, Jürgen Hoffmann
IntroductionMicrovascular surgery following tumor resection has become an important field of oral and maxillofacial surgery (OMFS). Following the results from management of T1/T2 floor-of-mouth and tongue squamous cell carcinoma (SCC) in German-speaking countries, Europe, and worldwide, this paper presents specific concepts for the management of resection and reconstruction of T3/T4 SCC of the maxillary and mandibular alveolar process and tongue.MethodsThe DÖSAK questionnaire was distributed in three different phases to a growing number of maxillofacial units worldwide. Within this survey, clinical patient settings were presented to participants and center-specific treatment strategies were evaluated.ResultsA total of 188 OMFS units from 36 different countries documented their treatment strategies for T3/T4 maxillary and mandibular alveolar process and tongue SCC. The extent of surgical resections and subsequent reconstructions is more consistent than with T1/T2 tumors, although the controversy surrounding continuity resections and mandible-sparing procedures remains. For continuity resection of the mandible the fibula free flap is the most frequently used bone replacement, whereas maxilla reconstruction concepts are less consistent, ranging from locoregional coverage concepts and different microvascular reconstruction options to treatment via obturator prosthesis.ConclusionResults from treatment strategies for T3/T4 tumors underline the limited evidence for the appropriate amount of resection and subsequent reconstruction process, especially in cases involving the mandible. Prospective randomized trials will be necessary in the long term to establish valid treatment guidelines.



http://ift.tt/2me4ogN